Читать книгу Clinical Pancreatology for Practising Gastroenterologists and Surgeons - Группа авторов - Страница 158

The demand for targeted pharmacological treatment in AP remains a high priority since none are currently available. Recent and ongoing determination of critical pathogenic mechanisms continues to support effective drug target evaluation. New molecular entities that inhibit calcium toxicity and repositioned drugs that block inflammatory pathways have progressed into clinical trials, the results of which are eagerly awaited. In addition, strategies targeting mitochondrial dysfunction hold significant promise. Key areas for improvement in clinical trial design have been identified, with inclusion of broader groups of patients that have AP and shorter door to needle times. Despite numerous hurdles in the progress of experimental medicine for AP, there is now visible light at the end of the tunnel sufficient for this important aspect of AP research to pick up speed.